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Background: Cardiovascular disease (CVD) is the main cause of death in patients on chronic dialysis. The question
whether dialysis modality impacts cardiovascular risk remains to be addressed. China Collaborative Study on
Dialysis, a multi-centers cohort study, was performed to evaluate cardiovascular morbidity during maintenance
hemodialysis (HD) and peritoneal dialysis (PD).
Method: The cohort consisted of chronic dialysis patients from the database of 9 of the largest dialysis facilities
around China. The inclusion period was between January 1, 2005, and December 1, 2010. Cardiovascular morbidity
was defined as the presence of clinically diagnosed ischemic heart disease, heart failure, peripheral vascular disease,
and/or stroke. The patients who had cardiovascular morbidity before initiation of dialysis were excluded. Data
collection was based on review of medical record.
Result: A total of 2,388 adult patients (1,775 on HD and 613 on PD) were enrolled. Cardiovascular morbidity
affected 57% patients and was comparable between HD and PD patients. However, clinically diagnosed ischemic
heart disease and stroke was more prevalent in PD than HD patients. When the patients were stratified by age or
dialysis vintage, the cardiovascular morbidity was significantly higher in PD than HD among those aged 50 years or
older, or those receiving dialysis over 36 months. Multivariate analysis revealed that the risk factors for
cardiovascular morbidity had different pattern in PD and HD patients. Hyperglycemia was the strongest risk factor
for cardiovascular morbidity in PD, but not in HD patients. Hypertriglyceridemia and hypoalbuminemia were
independently associated with CVD only in PD patients.
Conclusions: Cardiovascular morbidity during chronic dialysis was more prevalent in PD than HD patients among
those with old age and long-term dialysis. Metabolic disturbance-related risk factors were independently associated
with CVD only in PD patients. Better understanding the impact of dialysis modality on CVD would be an important
step for prevention and treatment.
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Cardiovascular disease (CVD) is the leading cause of
death among patients undergoing maintenance dialysis.
Compared with the general population, dialysis patients
have a 10 to 20 times greater incidence of cardiovascular
death [1-4]. The need to identify CVD and its risk fac-
tors in such population has never been greater.
Difference in the burden of cardiovascular morbidity
in dialysis patients among selected countries has been
described previously [5]. The prevalence of coronary ar-
tery disease in Asian dialysis population seems relatively
lower than that in patients from western countries [5-7].
The reason for the difference has not been clarified but
may correlate to the background cardiovascular morbid-
ity in their respective general population [8], as well as
the baseline characteristics of the dialysis population.
China is a country with huge population and increas-
ing burden of ESRD [9]. Our and others’ previous stud-
ies [6,7,9] have showed the characteristics of Chinese
dialysis population. Compared with the United States
and Europe where diabetes was the number one cause of
ESRD, the leading cause of ESRD in China is chronic
glomerulonephritis [6,7,9]. The average age of Chinese
dialysis patients was ten-years younger than those in
western countries [6,7]. It is reasonable to hypothesize
that the pattern of CVD and the risk factors for CVD in
Chinese dialysis patients might be different from that in
other ethnic populations. However, despite the large and
growing population of maintenance dialysis in China,
there has been lack of data on CVD in this population.
Risk factors for CVD in dialysis patients include those
that affect the general population (traditional risk factors)
and those related to end stage renal disease (ESRD) ( non-
traditional risk factors), as well as those that are specific to
chronic dialysis. Although the faster deterioration of CVD
in ESRD patients has been considered due mainly to accu-
mulation of traditional and non-traditional risk factors
[10-12], the question whether dialysis modality impacts
cardiovascular risk remains to be addressed. Cardiovascu-
lar disease is often present in patients initiating dialysis,
but may also develop during chronic dialysis treatment.
To address the relevant question, it is important to
know the impact of dialysis modality on outcome in
patients with existing CVD, and also, on emergence
of “de novo” CVD during dialysis. However, there are
few studies comparing CV risk of peritoneal dialysis
(PD) versus hemodialysis (HD) patients and evaluating
the impact of dialysis on development of CVD. Out-
lining the epidemiological data on CVD in patients
on HD and PD might be an important step to evalu-
ate the impact of dialysis modality on CVD.
The goal of the present study was to evaluate the preva-
lence of CVD in a representative Chinese population
undergoing maintenance dialysis. We also compared theprevalence and risk factors of CVD between patients on
HD and PD.
Results and discussion
Patient characteristics in the CCSD cohort
A total of 2,388 adult patients were enrolled in CCSD.
Both maintenance HD (n = 1,775) and PD (n = 613)
patients were included. The patient characteristics were
showed in Table 1. In this cohort, 1313 (55%) were male.
The mean age was 54 years old. The median time for
dialysis was 26 months (12–51 months). In regard to the
etiology of ESRD, primary glomerular disease was the
most frequent, affecting 1097 (45.9%) patients. Diabetes
was the second (21.4%). In this representative cohort,
the predominant patients (75%) were on HD and 25%
patients were on PD. Compared with HD patients, PD
patients were younger with shorter dialysis vintage. In
addition, hypertension, elevated BMI, and hypertriglycer-
idemia were more prevalent in PD patients.
Cardiovascular morbidity in the CCSD cohort
Cardiovascular morbidity was defined as any description
of clinically diagnosed ischemic heart disease, heart fail-
ure, stroke, or peripheral vascular disease in each med-
ical record from initiation of dialysis. As shown in
Table 2, cardiovascular morbidity affected 57% patients
in this cohort. Even though the overall cardiovascular
morbidity was comparable between HD and PD patients
(56.3% vs. 58.9%), the proportion of patients with ische-
mic heart disease and stroke was significantly more
prevalent in patients on PD than those on HD (Table 2).
Since development of CVD is a time-dependent
process and there was a difference in age and dialysis
vintage between HD and PD population, we further
compared the cardiovascular morbidity in patients strati-
fied by age and dialysis vintage, separately. As shown in
Figure 1A, the cardiovascular morbidity was significantly
more prevalent in PD than HD among those aged
50 years or older. The similar trend was observed in
clinically diagnosed heart failure, ischemic heart disease,
and stroke (Figure 1 B-D). When comparison was made
in patients stratified by dialysis vintage, the overall car-
diovascular morbidity, heart failure, and ischemic heart
disease were also more prevalent in PD than HD
patients among those receiving dialysis for more than
36 months (Figure 2A-C). The proportion of stroke was
significantly higher in PD compared to HD patients in
each category of dialysis vintage (Figure 2D). Since the
number of patients with peripheral artery disease was
limited, analysis according to stratification was not
performed.
In our cohort, the mean age of HD patients was higher
than that of PD population. Higher mortality in older
patients may result in lower cardiovascular morbidity in
Table 1 Characteristics of the Chinese dialysis patients a
Total Dialy is modality
(n=2388) PD (n=613) HD (n=1775) P
Demographic
Age, yr 54.1±15.3 51.0±15.0 55.1±15.3 <0.01
Male, n (%) 1313 (55.0 ) 309 (50.4) 1004 (56.6) <0.01
Smoker, n (%) 117 (4.9) 29 (4.7) 88 (5.0) 0.91
Diabetes, n (%) 548 (22.9) 136 (22.2) 412 (23.2) 0.62
Hypertension, n (%) 2013 (84.3) 566 (92.3) 1447 (81.5) <0.01
Dialysis vintage, mo 26 (12-51) 19 (9-35) 30 (13-60) <0.01
Dialysis adequacy, kt/v b 2.1±0.5 1.6±0.4 NA
Physical examination
Body mass index, kg/m2 21.7±3.4 22.1±3.2 21.5±3.4 <0.01
Systolic BP, mmHg 143.1±22.4 141.6±23.2 143.6±22.0 0.05
Diastolic BP, mmHg 83.4±13.1 83.1±13.1 83.5±13.1 0.57
Cause of renal failure, n (%)
Diabetes 512 (21.4) 129 (21.0) 383 (21.6) 0.82
Hypertension 406 (17.0) 113 (18.4) 293 (16.5) 0.29
Glomerular disease 1097 (45.9) 323 (52.7) 774 (43.6) <0.01
Tubulointerstitial disease 77 (3.2) 31 (5.1) 46 (2.6) <0.01
Connective tissue disease 48 (2.0) 11 (1.8) 37 (2.1) 0.74
Polycystic kidney disease 116 (4.9) 17 (2.8) 99 (5.6) <0.01
Others unknown causes 316 (13.2) 39 (6.4) 277 (15.6) <0.01
Laboratory assessments
Albumin, g/L 39.5±6.0 39.0±5.5 40.0±6.1 <0.01
Hemoglobin, g/L 104.3±20.5 106.8±20.8 103.5±20.3 <0.01
C-reactive protein, mg/L 3.6 (1.9-9.4) 3.1 (1.3-8.6) 3.9 (2.1-10.0) <0.01
Glucose, mM 4.8 (4.3-5.6) 4.8 (4.3-5.6) 4.9 (4.3-5.6) 0.33
Triglyceride, mM 1.4 (1.0-2.1) 1.5 (1.1-2.4) 1.3 (1.0-2.0) <0.01
LDL cholesterol, mM 2.4±0.8 2.8±0.8 2.3±0.7 <0.01
HDL cholesterol, mM 1.1±0.3 1.1±0.3 1.1±0.4 0.21
Serum phosphate, mM 2.0±0.5 2.0±0.5 2.0±0.6 0.18
Serum corrected calcium, Mm 2.2±0.2 2.3±0.2 2.2±0.2 0.17
iPTH, pg/ml 278.0 (138.5-572.4) 333.6 (171. 5-589.2) 260.1 (128.9-564.9) 0.72



















Table 1 Characteristics of the Chinese dialysis patients a (Continued)
Medication, n (%)
ACE inhibitors / ARBs 1217 (51.0) 363 (59.2) 854 (48.1) <0.01
β-blockers 1106 (46.3) 342 (55.8) 764 (43.0) <0.01
calcium channel blockers 1672 (70.0) 475 (77.5) 1197 (67.4) <0.01
erythropoietin 2036 (85.3) 546 (89.1) 1490 (83.9) <0.01
calcitriol 1004 (42.0) 252 (41.1) 752 (42.4) 0.60
phosphate-binding agents 967 (40.5) 255 (41.6) 712 (40.1) 0.54
lipid-lowering drugs 269 (11.3) 118 (19.2) 151 (8.5) <0.01
Aspirin 180 (7.5) 67 (10.9) 113 (6.4) <0.01
a: Continuous variables were expressed as mean ± SD for normally distributed data, median (25th percentile -75th percentile) for skewed data, while categorical variables were expressed as percentage (%).
b: kt/v is weekly in PD and per session in HD.




















Table 2 The cardiovascular morbidity in Chinese dialysis patients
Total Dialysis modality
(n=2388) PD (n=613) HD (n=1775) P
Cardiovascular morbidity, n (%)a 1361 (57.0) 361 (58.9) 1000 (56.3) 0.28
IHD 543 (22.7) 170 (27.7) 373 (21.0) <0.01
HF 1051 (44.0) 290 (47.3) 761 (42.9) 0.06
PVD 78 (3.3) 23 (3.8) 55 (3.1) 0.43
Stroke 230 (9.6) 82 (13.4) 148 (8.3) <0.01
a: Defined as any description of ischemic heart disease (IHD), heart failure (HF), stroke or peripheral vascular disease (PVD).
Abbreviation: HD, hemodialysis; PD, peritoneal dialysis.
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http://www.biomedcentral.com/1471-2369/13/94survivors. To reduce the bias, we compared mortality
during the evaluation period between HD and PD
patients. The annual rate of all-cause mortality was 8%
in HD and 10% in PD patients. The proportion of car-
diovascular death in total mortality was comparable be-
tween HD and PD population (52% vs. 48%).
Risk factors of CVD in the CCSD cohort
To identify the risk factors correlated with CVD, we
conducted a univariate and a multivariable logistic re-


































































Figure 1 Cardiovascular morbidity (A), heart failure (B), coronary hear
HD and PD patients. *P < 0.05 vs. HD patients.univariate analysis were shown in Table 3. Odds ratios
were obtained from logistic regression analysis. The risk
factors that were significant at P < 0.05 were then simul-
taneously entered into the stepwise logistic regression to
identify independent risk factors for CVD. As shown in
Table 4, the risk factors for cardiovascular morbidity in
this cohort included old age, smoking, hypertension,
Hypertriglyceridemia, low level of hemoglobin, and ele-
vated levels of C-reactive protein. It is interesting to note
that the risk factors of CVD showed different pattern in



















































t disease (C) and the stroke (D) in each category of age among
Table 3 Univariable logistic regression analysis: variables related to cardiovascular morbidity in dialysis patients
Variables Total (n=2388) PD (n=613) HD (n=1775)
OR (95% CI) P OR (95%CI) P OR (95%CI) P
Age ≥50 yr, (no=0, yes=1) 2.27 (1.91-2.69) <0.01 2.89 (2.07-4.03) <0.01 2.13 (1.75-2.60) <0.01
Gender (F=0, M=1) 1.07 (0.91-1.26) 0.39 1.00 (0.72-1.38) 1.00 1.09 (0.91-1.32) 0.35
Smoking (no=0, yes=1) 2.38 (1.55-3.65) <0.01 2.27 (0.96-5.40) 0.06 2.42 (1.48-3.96) <0.01
Hypertension (no=0, yes=1) 1.91 (1.53-2.39) <0.01 2.48 (1.34-4.57) <0.01 1.82 (1.43-2.32) <0.01
BMI ≥24.0kg/m2, (no=0, yes=1) 1.21 (1.00-1.47) 0.05 1.52 (1.04-2.22) 0.03 1.11 (0.88-1.39) 0.39
Glucose >7.0mM, (no=0, yes=1) 2.35 (1.73-3.21) <0.01 4.19 (2.21-7.98) <0.01 1.88 (1.31-2.69) <0.01
Triglyceride >1.7mM, (no=0, yes=1) 1.23 (1.02-1.47) 0.03 1.85 (1.31-2.60) <0.01 1.02 (0.82-1.28) 0.83
LDL cholesterol >3.36mM, (no=0, yes=1) 0.98 (0.74-1.29) 0.88 0.68 (0.46-1.02) 0.06 1.50 (0.49-2.27) 0.06
HDL cholesterol ≤0.92mM, (no=0, yes=1) 1.06 (0.87-1.30) 0.55 1.35 (0.92-1.97) 0.13 0.97 (0.76-1.23) 0.79
Albumin ≤35g/L, (no=0, yes=1) 1.36 (1.11-1.66) <0.01 2.18 (1.41-3.36) <0.01 1.18 (0.93-1.48) 0.17
Hemoglobin ≤90g/L, (no=0, yes=1) 1.33 (1.10-1.61) <0.01 0.82 (0.55-1.23) 0.34 1.54 (1.23-1.93) <0.01
C-reactive protein >3mg/L, (no=0, yes=1) 1.53 (1.25-1.87) <0.01 1.70 (1.20-2.41) <0.01 1.44 (1.13-1.84) <0.01
Ferritin, ng/ml 1.00 (1.00-1.00) 0.06 1.00 (0.99-1.00) 0.86 1.00 (1.00-1.00) 0.04
Dialysis vintage (mo) 1.00 (1.000-1.00) 0.15 1.01 (1.00-1.02) 0.02 1.00 (1.00-1.00) 0.05















































































































Figure 2 Cardiovascular morbidity (A), heart failure (B), coronary heart disease (C) and the stroke (D) in each category of dialysis
vintage among HD and PD patients. *P < 0.05 vs. HD patients.
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Table 4 Multivariable logistic regression analysis: variables related to cardiovascular morbidity in dialysis patients
Variables Total (n=2388) PD (n=613) HD (n=1775)
OR (95% CI) P OR (95%CI) P OR (95%CI) P
Age ≥50 yr, (no=0, yes=1) 2.31 (1.83-2.93) <0.01 2.27 (1.53-3.37) <0.01 2.45 (1.83-3.82) <0.01
Smoking (no=0, yes=1) 1.831 (1.26-2.67) <0.01 1.74 (1.18-2.56) <0.01
Hypertension (no=0, yes=1) 2.19 (1.57-3.05) <0.01 2.38 (1.12-5.03) 0.02 2.19 (1.51-3.15) <0.01
Glucose >7.0mM, (no=0, yes=1) 2.43 (1.22-2.62) 0.01
Triglyceride >1.7mM, (no=0, yes=1) 1.27 (1.00-1.62) <0.05 1.77 (1.19-2.62) <0.01
Albumin ≤35g/L, (no=0, yes=1) 1.87 (1.08-3.23) 0.03
Hemoglobin ≤90g/L, (no=0, yes=1) 1.43 (1.07-1.91) 0.02 1.64 (1.16-2.32) <0.01
C-reactive protein >3mg/L, (no=0, yes=1) 1.33 (1.05-1.68) 0.02 1.45 (1.09-1.92) 0.02
Abbreviation: HD, hemodialysis; PD, peritoneal dialysis; OR, odds ratio; CI, confidence interval.
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but not in HD patients. Hypertriglyceridemia and
hypoalbuminemia were the independent risk factors for
CVD only in PD population (Table 4).
Discussion
We found in the present study that cardiovascular mor-
bidity prevalence remains as high as 57% in Chinese dia-
lysis population, even with less diabetes and more
glomerulonephritis comparing to Western countries.
Compared to HD patients, PD patients had more preva-
lent CVD among those aged 50 years or older and those
receiving dialysis for more than 36 months. The risk fac-
tors for cardiovascular morbidity in PD patients had dif-
ferent pattern compared to HD population.
The question whether dialysis modality impacts the
risk of CVD remains to be addressed. It is important to
know the impact of dialysis modality not only on out-
come in patients with existing CVD, but also on emer-
gence of “de novo” CVD during dialysis. However, there
are few studies evaluating the development of CVD in
dialysis patients. Our study found that clinically diag-
nosed CVD after initiation of dialysis was more preva-
lent than expected. The ischemic heart disease was
22.7%, heart failure 44%, stroke 9.6%, and peripheral
artery disease 3.3%. Heart failure was the most preva-
lent cardiovascular morbidity occurred during chronic
dialysis.
Studies comparing the outcomes with PD and HD
patients have shown conflicting results [13-15], probably
due to difference in study populations (incident or
prevalent dialysis patients) or methodology. Therefore,
valid comparison between HD and PD requires patient
stratification according to the major risk factors [16].
The present study showed that the overall cardiovascular
morbidity was comparable between HD and PD patients.
However, this result could be biased by the difference in
age and dialysis vintage between patients on the two dia-
lysis modality since CVD is a time-dependent process.To reduce such bias, we classified the patients by age
and dialysis vintage. We found that cardiovascular mor-
bidity and its composites such as heart failure, ischemic
heart disease, and stroke were significantly higher in PD
compared to HD patients among those aged 50 years or
older and those receiving dialysis for more than 3 years.
The lower cardiovascular morbidity in HD patients was
not related with high mortality since annual rate of all-
cause and cardiovascular mortality was relatively lower
in patients on HD.
The reasons for the increased cardiovascular morbid-
ity in our PD patients remained elusive. There might be
two explanations. First, the PD patients enrolled in the
study were all treated by the conventional PD solu-
tion containing high concentration of glucose, since
icodextrin- or amino acid-based dialysate is not com-
mercially available in China. Long-term exposure to
high level of glucose or glucose degradation products
may lead to cumulative metabolic stress and resulting
in development or worsening of CVD [17,18]. This
hypothesis was supported by the fact that hypergly-
cemia served as the strongest independent risk factor
in the multiple logistic regression model than the
other known risk factors. Furthermore, increased BMI
and hypertriglyceridemia were more common in PD
than HD patients. Alternatively, the prevalence of
hypertension, probably reflecting an inadequate con-
trol of fluid volume, was more common in PD than
HD patients in our population (92.3% vs. 81.5%).
The risk factors for CVD specifically related to chronic
dialysis have not been well established. Traditional and
non-traditional CVD risk factors were both identified in
our cohort. However, the prevalence of traditional risk
factors such as diabetes, smoking, higher BMI, and
hyperlipidemia was less frequent as compared with dia-
lysis population in western countries [5,19]. Meanwhile,
uremia-related risk factors seemed more prevalent in
our cohort. Even though erythropoietin was widely used
(85%), anemia was very common in Chinese dialysis
Hou et al. BMC Nephrology 2012, 13:94 Page 8 of 9
http://www.biomedcentral.com/1471-2369/13/94patients. The mean level of hemoglobin in the present
cohort was below 120 g/L, an optimal target recom-
mended by KDOQI [20].
In the multivariate logistic regression analysis, the risk
factors for cardiovascular morbidity in this cohort
included old age, smoking, hypertension, hypertriglyceri-
demia, low level of hemoglobin, and elevated levels of
C-reactive protein. It is interesting to note that the risk
factors of CVD had different pattern between PD and
HD patients. Metabolic disturbance-related risk factors,
such as hyperglycemia, hypertriglyceridemia and hypoal-
buminemia, were independently associated with cardio-
vascular morbidity only in PD patients. It has been
shown that high glucose load and the presence of glu-
cose degradation in conventional PD solution may lead
to accumulation of advanced glycation end products
which has been implicated in the development of CVD
[17,18].
In the present study, the dialysis modality was not ran-
domly selected and was affected by economic and social
status as well as access to medical center. To confirm
the impact of dialysis modality on CVD, a randomized
control study would be needed. To reduce case mixed-
related bias, this study included patients from nine of
the largest dialysis facilities in China. Therefore, the
results may only reflect the characteristic of dialysis
population in academic and central dialysis facilities in
China.
Conclusion
We demonstrated that cardiovascular morbidity during
chronic dialysis was higher than expected in a Chinese
population. The cardiovascular morbidity was more
prevalent in PD than HD patients among those over
50 years of age and those receiving dialysis for 3 years or
more. The risk factors for CVD showed different pattern
between PD and HD patients. Metabolic disturbance-
related risk factors, such as hyperglycemia, hypertrigly-
ceridemia and hypoalbuminemia, were independently
associated with cardiovascular morbidity only in PD
patients. Since CVD remains the leading cause of death
in dialysis population worldwide, understanding the im-
pact of dialysis modality on CVD in different population




The study cohort consisted of chronic patients from the
hospital database of 9 of the largest dialysis facilities (the
number of patients on HD ≥200 or PD ≥100) in 6 cities
around China (Beijing, Shanghai, Guangzhou, Hangzhou,
Wuhan, and Xian). The inclusion period for the present
study was between January 1, 2005, and December 1, 2010.Among the cohort, 5.6% (HD, n= 125; PD, n= 8) of
patients had been on chronic dialysis before transferred to
the selected facility. Appropriate approval was obtained
from the local ethics committee.
All adult (older than 18 years) patients with ESRD
undergoing dialysis for at least 3 months in the selected fa-
cilities were enrolled. The patients who had clinically diag-
nosed ischemic heart disease, heart failure, stroke, and
peripheral vascular disease at initiation of dialysis were
excluded. Ischemic heart disease was defined as the pres-
ence of myocardial infarction, coronary revascularization
procedures, angina, and ischemia on electrocardiogram or
other diagnostic tests [5]. The diagnosis of heart failure
was based on an ejection fraction below 40% or New York
Heart Association Criteria grade 3 or more [21]. Peripheral
vascular disease was defined as the presence of amputation
of digits or extremities secondary to vascular disease, per-
ipheral arterial bypass or angioplasty, intermittent claudica-
tion, recurrent cellulitis secondary to vascular disease [22].
A total of 2,388 (1,775 on HD and 613 on PD) patients
were analyzed.
Data collection
All data were collected at enrollment on the bases of re-
view of medical records. All records were abstracted by
two experienced dialysis research nurses. The following
data were collected: demographic data, underlying renal
diseases, medication records, dialysis modality, dialysis
program, and cardiovascular morbidity which was defined
as the presence of clinically diagnosed ischemic heart dis-
ease, heart failure, peripheral vascular disease, and/or
stroke after initiation of dialysis.
Hematology and biochemistry measurements, time-
averaged over the latest 3 months, were recorded. Fasting
venous serum specimens were collected before dialysis
session in HD patients or at the clinical visit in PD
patients. Blood test was performed by the clinical labora-
tories in individual dialysis facilities.
Blood pressure measurement was taken before each of
the three HD sessions or each of the three PD visits, all
after 10 minutes of rest in a supine decubitus position.
Dialysis regimens
Patients maintained on HD were dialyzed twice or thrice
weekly with low-flux polysulphone or polyacrylamide dia-
lyzer, either 1.5 or 1.7 m2 (Fresenius, Germany; Gambro,
Sweden; Nipro, Japan; B. Braun, Germany; Langsheng,
China). All treatments were of 4-hour to 5-hour duration
with conventional glucose-free, bicarbonate-based dialysate
containing 1.25 mM-1.5 mM calcium, 2.0 mM potassium,
and 138 mM sodium. Dialysate flow was 500 ml/min.
All PD patients used lactate-buffered, 1.36% to 3.86%
glucose-containing solutions (Baxter) as prescribed for
routine clinical care. Patients were followed up every
1 ~ 3 months in each center.
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Statistical analyses were performed with SPSS 13.0 for
WindowsW. Descriptive statistics that used means, med-
ians, proportions, SE, and confidence intervals were per-
formed on all variables where appropriate. The continuous
data were presented as the mean± standard deviation or
the median and interquartile ranges where appropriate.
Categorical variables are presented as percentages. We
compared two groups using the Student’s t test or the
Mann–Whitney test where appropriate. The Pearson χ2
test and the Kruskal-Wallis test were applied for analysis
of nominal and ordinal variables respectively. The odd
ratios describing the association of selected risk factors
with CVD were obtained by the univariable and multivari-
able logistic regression analysis, respectively.
Abbreviation
CVD: Cardiovascular disease; HD: Hemodialysis; PD: Peritoneal dialysis;
CCSD: China cooperate study on dialysis.
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